Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes

被引:0
作者
Sietse M. Aukema
Selina Glaser
Mari F. C. M. van den Hout
Sonja Dahlum
Marinus J. Blok
Morten Hillmer
Julia Kolarova
Raf Sciot
Dina A. Schott
Reiner Siebert
Constance T. R. M. Stumpel
机构
[1] Maastricht University Medical Centre (MUMC+),Department of Clinical Genetics
[2] Ulm University and Ulm University Medical Center,Institute of Human Genetics
[3] Research Institute GROW,Department of Pathology
[4] Maastricht University Medical Center,Department of Pathology
[5] University Hospital,Department of Pediatrics
[6] University of Leuven,Department of Clinical Genetics and GROW
[7] Zuyderland Medical Center,School for Oncology & Developmental Biology
[8] Maastricht University Medical Center+,undefined
来源
Familial Cancer | 2023年 / 22卷
关键词
Kabuki syndrome; KMT2D; Tumor predisposition; Rhabdomyosarcoma; Methylation;
D O I
暂无
中图分类号
学科分类号
摘要
Kabuki syndrome is a well-recognized syndrome characterized by facial dysmorphism and developmental delay/intellectual disability and in the majority of patients a germline variant in KMT2D is found. As somatic KMT2D variants can be found in 5–10% of tumors a tumor predisposition in Kabuki syndrome is discussed. So far less than 20 patients with Kabuki syndrome and a concomitant malignancy have been published. Here we report on a female patient with Kabuki syndrome and a c.2558_2559delCT germline variant in KMT2D who developed an embryonal rhabdomyosarcoma (ERMS) at 10 years. On tumor tissue we performed DNA-methylation profiling and exome sequencing (ES). Copy number analyses revealed aneuploidies typical for ERMS including (partial) gains of chromosomes 2, 3, 7, 8, 12, 15, and 20 and 3 focal deletions of chromosome 11p. DNA methylation profiling mapped the case to ERMS by a DNA methylation-based sarcoma classifier. Sequencing suggested gain of the wild-type KMT2D allele in the trisomy 12. Including our patient literature review identified 18 patients with Kabuki syndrome and a malignancy. Overall, the landscape of malignancies in patients with Kabuki syndrome was reminiscent of that of the pediatric population in general. Histopathological and molecular data were only infrequently reported and no report included next generation sequencing and/or DNA-methylation profiling. Although we found no strong arguments pointing towards KS as a tumor predisposition syndrome, based on the small numbers any relation cannot be fully excluded. Further planned studies including profiling of additional tumors and long term follow-up of KS-patients into adulthood could provide further insights.
引用
收藏
页码:103 / 118
页数:15
相关论文
共 411 条
  • [1] Adam MP(2019)Kabuki syndrome: international consensus diagnostic criteria J Med Genet 56 89-95
  • [2] Banka S(2013)MLL2 and KDM6A mutations in patients with Kabuki syndrome Am J Med Genet A 161A 2234-2243
  • [3] Bjornsson HT(2016)Mutation update for Kabuki syndrome genes KMT2D and KDM6A and further delineation of X-linked Kabuki syndrome subtype 2 Hum Mutat 37 847-864
  • [4] Miyake N(2021)Clinical delineation, sex differences, and genotype-phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2 Genet Med 66 e27916-1037
  • [5] Koshimizu E(2020)Genetic control of tumor development in malformation syndromes Am J Med Genet A 173 1017-65
  • [6] Okamoto N(2019)How I approach hereditary cancer predisposition in a child with cancer Pediatr Blood Cancer 5 1-385.e18
  • [7] Bögershausen N(2017)Childhood cancer predisposition syndromes-a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology Am J Med Genet A 458 56-239
  • [8] Gatinois V(2019)Rhabdomyosarcoma Nat Rev Dis Prim 173 371-604
  • [9] Riehmer V(2020)Germline cancer-predisposition variants in pediatric rhabdomyosarcoma: a report from the children’s oncology group J Natl Cancer Inst 12 5961-2016
  • [10] Faundes V(2019)COMPASS ascending: emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer Cancer Lett 18 224-463